Prazosin: Your brand is changing to Apo-Prazosin

Same active ingredient, in the same amount

Apo-Prazosin is Medsafe approved. Medsafe has reviewed it and found that it meets New Zealand standards of safety, quality, and effectiveness.

Apo-Prazosin comes as a tablet

Unlike the Mylan brand, Apo-Prazosin is a tablet. It is designed to work in your body the same way as Mylan Prazosin. You should not notice any difference when you change brand. If you do, please talk to the person who prescribed it.

You may have taken this brand before

If you were taking prazosin before 2023, this brand is the same product as the originally funded brand. There was a fire at the factory which meant it could not be supplied for a few years. 

Pharmacists: What you need to know

The new Apo-Prazosin has the same Pharmacodes as the Arrotex-Prazosin S29. From 1 October 2026,

• the existing Pharmacodes will be updated to the Apo-Prazosin brand
• the S29 and wastage rules will be removed. 

Mylan brand remains available throughout October 2026

Viatris will keep supplying the Mylan brand of prazosin until the end of October 2026. Stock is expected to last until the end of October 2026, ensuring people can continue to access this treatment. Mylan will not be delisted for some time to allow time for it to be dispensed and claimed. 

Flyer available

You can download an A4 Flyer to support conversations with affected people.

Who to contact

If you have questions about this change, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)